# Astera Labs, Inc.: financial statements, quarterly

ALAB · Nasdaq · CIK 1736297 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alab.md) · [Financials](/companies/alab/financials.md) · [Filings](/companies/alab/filings.md) · [Insiders](/companies/alab/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/alab/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [36.9](/filings/0001736297-24-000043.md) | [50.5 d](/filings/0001736297-26-000010.md) | [65.3](/filings/0001736297-25-000031.md) | [76.9](/filings/0001736297-25-000098.md) | [113](/filings/0001736297-25-000147.md) | [141 d](/filings/0001736297-26-000010.md) | [159](/filings/0001736297-26-000020.md) | [192](/filings/0001736297-26-000035.md) | [231](/filings/0001736297-25-000147.md) | [271 d](/filings/0001736297-26-000010.md) | [308](/filings/0001736297-26-000020.md) | [392](/filings/0001736297-26-000035.md) |
| Cost of revenue | $m | [8.8](/filings/0001736297-24-000043.md) | [11.5 d](/filings/0001736297-26-000010.md) | [14.7](/filings/0001736297-25-000031.md) | [17.0](/filings/0001736297-25-000098.md) | [25.2](/filings/0001736297-25-000147.md) | [36.6 d](/filings/0001736297-26-000010.md) | [40.0](/filings/0001736297-26-000020.md) | [46.4](/filings/0001736297-26-000035.md) | [54.8](/filings/0001736297-25-000147.md) | [66.1 d](/filings/0001736297-26-000010.md) | [73.2](/filings/0001736297-26-000020.md) | [105](/filings/0001736297-26-000035.md) |
| Gross profit | $m | [28.1](/filings/0001736297-24-000043.md) | [39.0 d](/filings/0001736297-26-000010.md) | [50.5](/filings/0001736297-25-000031.md) | [59.9](/filings/0001736297-25-000098.md) | [87.9](/filings/0001736297-25-000147.md) | [104 d](/filings/0001736297-26-000010.md) | [119](/filings/0001736297-26-000020.md) | [146](/filings/0001736297-26-000035.md) | [176](/filings/0001736297-25-000147.md) | [204 d](/filings/0001736297-26-000010.md) | [235](/filings/0001736297-26-000020.md) | [288](/filings/0001736297-26-000035.md) |
| Research and development | $m | [20.6](/filings/0001736297-24-000043.md) | [19.7 d](/filings/0001736297-26-000010.md) | [53.6](/filings/0001736297-25-000031.md) | [40.1](/filings/0001736297-25-000098.md) | [50.7](/filings/0001736297-25-000147.md) | [56.5 d](/filings/0001736297-26-000010.md) | [64.6](/filings/0001736297-26-000020.md) | [66.7](/filings/0001736297-26-000035.md) | [78.9](/filings/0001736297-25-000147.md) | [93.8 d](/filings/0001736297-26-000010.md) | [126](/filings/0001736297-26-000020.md) | [136](/filings/0001736297-26-000035.md) |
| Operating income | $m | [(2.0)](/filings/0001736297-24-000043.md) | [9.0 d](/filings/0001736297-26-000010.md) | [(83.0)](/filings/0001736297-25-000031.md) | [(24.3)](/filings/0001736297-25-000098.md) | [(8.9)](/filings/0001736297-25-000147.md) | [0.1 d](/filings/0001736297-26-000010.md) | [11.3](/filings/0001736297-26-000020.md) | [39.8](/filings/0001736297-26-000035.md) | [55.4](/filings/0001736297-25-000147.md) | [67.0 d](/filings/0001736297-26-000010.md) | [61.8](/filings/0001736297-26-000020.md) | [89.2](/filings/0001736297-26-000035.md) |
| Income tax | $m | [2.9](/filings/0001736297-24-000043.md) | [(3.6) d](/filings/0001736297-26-000010.md) | [12.6](/filings/0001736297-25-000031.md) | [(6.5)](/filings/0001736297-25-000098.md) | [9.6](/filings/0001736297-25-000147.md) | [(14.0) d](/filings/0001736297-26-000010.md) | [(10.1)](/filings/0001736297-26-000020.md) | [(0.6)](/filings/0001736297-26-000035.md) | [(24.3)](/filings/0001736297-25-000147.md) | [33.9 d](/filings/0001736297-26-000010.md) | [(6.9)](/filings/0001736297-26-000020.md) | [(50.3)](/filings/0001736297-26-000035.md) |
| Net income | $m | [(3.1)](/filings/0001736297-24-000043.md) | [14.3 d](/filings/0001736297-26-000010.md) | [(93.0)](/filings/0001736297-25-000031.md) | [(7.5)](/filings/0001736297-25-000098.md) | [(7.6)](/filings/0001736297-25-000147.md) | [24.7 d](/filings/0001736297-26-000010.md) | [31.8](/filings/0001736297-26-000020.md) | [51.2](/filings/0001736297-26-000035.md) | [91.1](/filings/0001736297-25-000147.md) | [45.0 d](/filings/0001736297-26-000010.md) | [80.3](/filings/0001736297-26-000020.md) | [153](/filings/0001736297-26-000035.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001736297-24-000043.md) | not reported | [(1.77)](/filings/0001736297-25-000031.md) | [(0.05)](/filings/0001736297-25-000098.md) | [(0.05)](/filings/0001736297-25-000147.md) | not reported | [0.18](/filings/0001736297-26-000020.md) | [0.29](/filings/0001736297-26-000035.md) | [0.50](/filings/0001736297-25-000147.md) | not reported | [0.44](/filings/0001736297-26-000020.md) | [0.83](/filings/0001736297-26-000035.md) |
| Basic EPS | $ per share | [(0.08)](/filings/0001736297-24-000043.md) | not reported | [(1.77)](/filings/0001736297-25-000031.md) | [(0.05)](/filings/0001736297-25-000098.md) | [(0.05)](/filings/0001736297-25-000147.md) | not reported | [0.19](/filings/0001736297-26-000020.md) | [0.31](/filings/0001736297-26-000035.md) | [0.54](/filings/0001736297-25-000147.md) | not reported | [0.47](/filings/0001736297-26-000020.md) | [0.89](/filings/0001736297-26-000035.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [45.1](/filings/0001736297-25-000003.md) | [696](/filings/0001736297-24-000006.md) | [421](/filings/0001736297-24-000018.md) | [126](/filings/0001736297-24-000043.md) | [79.6](/filings/0001736297-26-000010.md) | [86.4](/filings/0001736297-25-000031.md) | [162](/filings/0001736297-25-000098.md) | [140](/filings/0001736297-25-000147.md) | [168](/filings/0001736297-26-000035.md) | [148](/filings/0001736297-26-000020.md) | [111](/filings/0001736297-26-000035.md) |
| Current assets | $m | not reported | [186](/filings/0001736297-25-000003.md) | [854](/filings/0001736297-24-000006.md) | [891](/filings/0001736297-24-000018.md) | [946](/filings/0001736297-24-000043.md) | [1,013](/filings/0001736297-26-000010.md) | [1,076](/filings/0001736297-25-000031.md) | [1,181](/filings/0001736297-25-000098.md) | [1,290](/filings/0001736297-25-000147.md) | [1,362](/filings/0001736297-26-000035.md) | [1,413](/filings/0001736297-26-000020.md) | [1,652](/filings/0001736297-26-000035.md) |
| Total assets | $m | not reported | [196](/filings/0001736297-25-000003.md) | [865](/filings/0001736297-24-000006.md) | [916](/filings/0001736297-24-000018.md) | [983](/filings/0001736297-24-000043.md) | [1,055](/filings/0001736297-26-000010.md) | [1,122](/filings/0001736297-25-000031.md) | [1,271](/filings/0001736297-25-000098.md) | [1,401](/filings/0001736297-25-000147.md) | [1,532](/filings/0001736297-26-000035.md) | [1,659](/filings/0001736297-26-000020.md) | [1,932](/filings/0001736297-26-000035.md) |
| Current liabilities | $m | not reported | [35.1](/filings/0001736297-25-000003.md) | [45.6](/filings/0001736297-24-000006.md) | [64.1](/filings/0001736297-24-000018.md) | [88.0](/filings/0001736297-24-000043.md) | [86.5](/filings/0001736297-26-000010.md) | [77.3](/filings/0001736297-25-000031.md) | [106](/filings/0001736297-25-000098.md) | [101](/filings/0001736297-25-000147.md) | [133](/filings/0001736297-26-000035.md) | [125](/filings/0001736297-26-000020.md) | [164](/filings/0001736297-26-000035.md) |
| Total liabilities | $m | not reported | [38.9](/filings/0001736297-25-000003.md) | [56.1](/filings/0001736297-24-000006.md) | [70.3](/filings/0001736297-24-000018.md) | [93.5](/filings/0001736297-24-000043.md) | [89.7](/filings/0001736297-26-000010.md) | [80.1](/filings/0001736297-25-000031.md) | [136](/filings/0001736297-25-000098.md) | [129](/filings/0001736297-25-000147.md) | [168](/filings/0001736297-26-000035.md) | [165](/filings/0001736297-26-000020.md) | [206](/filings/0001736297-26-000035.md) |
| Shareholders' equity | $m | [(117)](/filings/0001736297-24-000043.md) | [(97.7)](/filings/0001736297-26-000010.md) | [809](/filings/0001736297-25-000098.md) | [845](/filings/0001736297-25-000147.md) | [890](/filings/0001736297-25-000147.md) | [965](/filings/0001736297-26-000035.md) | [1,042](/filings/0001736297-26-000035.md) | [1,136](/filings/0001736297-26-000035.md) | [1,272](/filings/0001736297-25-000147.md) | [1,364](/filings/0001736297-26-000035.md) | [1,494](/filings/0001736297-26-000035.md) | [1,726](/filings/0001736297-26-000035.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(0.3) d](/filings/0001736297-24-000043.md) | [14.4 d](/filings/0001736297-26-000010.md) | [3.7](/filings/0001736297-25-000031.md) | [29.8 d](/filings/0001736297-25-000098.md) | [63.5 d](/filings/0001736297-25-000147.md) | [39.7 d](/filings/0001736297-26-000010.md) | [10.5](/filings/0001736297-26-000020.md) | [135 d](/filings/0001736297-26-000035.md) | [78.2 d](/filings/0001736297-25-000147.md) | [95.3 d](/filings/0001736297-26-000010.md) | [74.6](/filings/0001736297-26-000020.md) | [87.7 d](/filings/0001736297-26-000035.md) |
| Capital expenditure | $m | [0.7 d](/filings/0001736297-24-000043.md) | [1.0 d](/filings/0001736297-26-000010.md) | [3.4](/filings/0001736297-25-000031.md) | [(1.3) d](/filings/0001736297-25-000098.md) | [16.7 d](/filings/0001736297-25-000147.md) | [15.4 d](/filings/0001736297-26-000010.md) | [4.5](/filings/0001736297-26-000020.md) | [2.0 d](/filings/0001736297-26-000035.md) | [12.3 d](/filings/0001736297-25-000147.md) | [18.7 d](/filings/0001736297-26-000010.md) | [7.6](/filings/0001736297-26-000020.md) | [20.5 d](/filings/0001736297-26-000035.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [35.8](/filings/0001736297-24-000006.md) | [36.6](/filings/0001736297-24-000018.md) | [37.5](/filings/0001736297-24-000043.md) | [52.5](/filings/0001736297-25-000031.md) | [155](/filings/0001736297-25-000098.md) | [157](/filings/0001736297-25-000147.md) | [178](/filings/0001736297-26-000020.md) | [178](/filings/0001736297-26-000035.md) | [181](/filings/0001736297-25-000147.md) | [181](/filings/0001736297-26-000020.md) | [183](/filings/0001736297-26-000035.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 173,485,104 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001736297-26-000035.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.